Compare FSP & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | BWAY |
|---|---|---|
| Founded | 1981 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 337.9M |
| IPO Year | N/A | 2019 |
| Metric | FSP | BWAY |
|---|---|---|
| Price | $0.94 | $19.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 450.0K | 72.6K |
| Earning Date | 02-10-2026 | 11-11-2025 |
| Dividend Yield | ★ 4.26% | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | ★ $109,497,000.00 | $49,094,000.00 |
| Revenue This Year | $4.36 | $330.76 |
| Revenue Next Year | $0.81 | $22.24 |
| P/E Ratio | ★ N/A | $61.62 |
| Revenue Growth | N/A | ★ 27.08 |
| 52 Week Low | $0.85 | $7.84 |
| 52 Week High | $2.09 | $19.80 |
| Indicator | FSP | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 65.96 |
| Support Level | $0.85 | $15.97 |
| Resistance Level | $1.01 | $19.80 |
| Average True Range (ATR) | 0.06 | 0.79 |
| MACD | 0.01 | 0.23 |
| Stochastic Oscillator | 57.54 | 87.73 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.